






Supplemental Figure 1. Representative images of sections from normal (top) and IPF (bottom) human lungs showing CHP fluorescent co-localization with (A) CD206 to label macrophages or (B) PDGFR- α to label fibroblasts. Scale bars indicate 50 μ m.



Supplemental Figure 2. (A) Representative 10x trichrome images of saline and bleomycin-injured lung tissues at peak fibrosis (d 21), mid-resolution (d 42) and full resolution (d 63) time points. Images are representative of an n of 4 mice for each treatment group. Scale bars represent 200 μ m. **(B)** Representative images of sections from normal (left) and IPF (right) human lungs showing MRC2 fluorescence co-staining with collagen I telopeptide indicating fibrillar intact collagen. Scale bars indicate 50 μ m.



Supplemental Figure 3. (A) MRC2 knockdown efficiency by immunoblot analysis in TGF- β -elicited MFs that underwent CRISPR-mediated MRC2 silencing. **(B)** Immunoblot analysis of MRC2 in IPF MFs after 1-24 h of dedifferentiating agent treatment. Each data point is derived from an independent patient cell line. **(C)** MRC2 immunoblot analysis of TGF- β -elicited MFs at baseline and **(D)** after dedifferentiation induced by PGE₂ and FGF2. Immunoblot images in **(D)** were run on the same gel, but were noncontiguous, as designated by the solid black line between lanes. Significance in **A** & **C** was determined by 2-tailed t-test, while that in **B** & **D** was determined by 1-way ANOVA. * p<0.05, **** p<0.0001.

944 **Supplemental Table 1.**

Age and Sex Characteristics of Patients from whom Lung Fibroblasts were Obtained			
	Sex Distribution:		Mean Age $\pm$ SEM (years):
Normal lung derived fibroblasts	Male	15 (62.50%)	40.80 $\pm$ 4.41
	Female	9 (37.50%)	44.40 $\pm$ 4.97
IPF lung derived fibroblasts	Male	18 (81.82%)	57.04 $\pm$ 2.40
	Female	4 (18.18%)	58.5 $\pm$ 3.38
Fisher's Exact Test:		p=0.1968	p>0.9999

945